Market Overview

UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

Related AMRN
Amarin Announces Agreement to Purchase $16.2M of Its Existing Exchangeable Notes and Pricing of $31.3 Million of New Exchangeable Notes
Amarin Popped Amid Press Release In Friday's After-Hours Session

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on Amarin (NASDAQ: AMRN), but lowered the price target from $24.00 to $20.00.

In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”

Amarin closed on Thursday at $5.31.

Latest Ratings for AMRN

Mar 2015HC WainwrightUpgradesBuy
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Jefferies Thomas WeiAnalyst Color Price Target Analyst Ratings


Related Articles (AMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters